| Literature DB >> 25952029 |
Dorota Olczak-Kowalczyk1, Beata Pyrżak2, Maria Dąbkowska3, Małgorzata Pańczyk-Tomaszewska4, Grażyna Miszkurka5, Izabela Rogozińska6, Ewa Swoboda-Kopeć7, Dariusz Gozdowski8, Angelika Kalińska9, Anna Piróg10, Małgorzata Mizerska-Wasiak11, Maria Roszkowska-Blaim12.
Abstract
BACKGROUND: Diabetes and Nephrotic syndrome (NS) promote plaque-related gingivitis and yeast-like fungal infections. The study assesses the impact of Candida spp. and general disease- or treatment-related factors on plaque-related gingivitis severity in children and adolescents with Nephrotic syndrome /diabetes.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25952029 PMCID: PMC4425863 DOI: 10.1186/s12903-015-0042-6
Source DB: PubMed Journal: BMC Oral Health ISSN: 1472-6831 Impact factor: 2.757
Age and sex of patients qualified to the study and biochemical characteristics of children with nephrotic syndrome or type 1 diabetes
|
|
|
|
|
|
|---|---|---|---|---|
| Control group | 29 (10/19) | 3-17.1 (11.52 ± 4.01 ) | - | - |
| Nephrotic syndrome | 32 (13/19) | 3-18 (10.05 ± 4.8) | Proteinuria (mg/kg/day) | 73.2 ± 104.24 |
| Albumin (g/dL) | 3.54 ± 0.84 | |||
| Total protein (g/dL) | 6.4 ± 1.17 | |||
| Haemoglobin (g%) | 13.73 ± 1.46 | |||
| Hematocrit (%) | 41.74 ± 4.37 | |||
| Leukocyte count (x103/mm3) | 9.8 ± 3.16 | |||
| Cholesterol (mg/dL) | 262.29 ± 127.33 | |||
| Triglycerides (mg/dL) | 176.33 ± 165.23 | |||
| Type 1 diabetes | 35 (17/18) | 6-17.9 (13.24 ± 2.64) | Blood glucose level (mg/dL) | 173.94 ± 70.3 |
| HbA1c (%) | 8.93 ± 2.16 |
Candida spp. prevalence and activity of Candida enzymes isolated from the oral cavity in patients from the control group (C), with Nephrotic syndrome (NS), and with type 1 diabetes (D1)
|
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
| ||
|
|
| ||||||||
| NS | 11/34.37 | 11/34.37 | 8/25.00 | 11 | 1 | 9 | 5 | 10 | 6 |
| D1 | 8/22.86 | 7/20.0 | 6/17.14 | 7 | 0 | 7 | 4 | 9 | 4 |
| C | 12/41.37 | 10/34.48 | 2/6.89 | 11 | 0 | 10 | 0 | 10 | 2 |
| P-value - chi-squared test | |||||||||
| NS vs C | 0.573 | 0.993 | 0.057 | 0.773 | 0.337 | 0.592 | 0.026* | 0.788 | 0.171 |
| D1 vs C | 0.111 | 0.192 | 0.217 | 0.112 | 1.000 | 0.192 | 0.060 | 0.445 | 0.536 |
*significantly different at P < 0.05.
Oral hygiene (PLI) and gingivae condition (GI) in patients from groups: with nephrotic syndrome (NS), with diabetes (D1), and control (C)
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|
| PL I | mean ± SD | 0.98 ± 0.61 | 1.02 ± 0.51 | 0.53 ± 0.69 | NS vs C | 0.011* |
| D1 vs C | 0.002* | |||||
| GI | 0.62 ± 0.69 | 0.47 ± 0.38 | 0.24 ± 0.42 | NS vs C | 0.014* | |
| D1 vs C | 0.026* | |||||
| GI ≥ 0.1 | n/% | 20/62.5 | 28/80.0 | 11/37.93 | NS vs C | 0.055 |
| D1 vs C | 0.001* | |||||
| GI ≥ 1.1 | 10/31.25 | 4/11.43 | 1/3.45 | NS vs C | 0.005* | |
| D1 vs C | 0.236 | |||||
| Correlation between PL I and GI | 0.482* | 0.633* | 0.670* | - | ||
| (P < 0.001) | (P < 0.001) | (P < 0.001) | ||||
*significantly different at P < 0.05; the t-test was used to compare means, and the chi-squared test to compare fractions.
Kendall Tau correlation coefficients (KTC) and partial standardized coefficient of multiple regression (MR) between GI and . occurrence, candidal enzymatic activity in oral cavity, and systemic factors (immunosuppressive treatment, selected clinical and biochemical parameters) in the NS and C, NS, D1 and C, and D1 groups
|
|
|
|
|
| |||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| ||
|
| 0.046 | −0.042 | 0.082 | 0.080 | 0.180* | −0.341 | 0.243* | −0.708 | |
| Enzymatic activity of Candida spp. isolated from the oral cavity | E7 | 0.222* | 0.189 | 0.098 | 0.053 | 0.272* | 0.211 | 0.463 | |
| code 5 | −0.010 | −0.343* | −0.060 | −0.344 |
| - | |||
| E16 | 0.215* | 0.385 | 0.070 | −0.220 | 0.316* | 0.678 | 0.417* | 0.424 | |
| code 5 | 0.094 | −0.403 | 0.025 | 0.083 | 0.283* | −0.173 | 0.377* | −0.065 | |
| E18 | 0.259* | −0.143 | 0.134 | −0.377 | 0.260* | −0.067 | 0.295* | 0.648 | |
| code 5 | 0.273* | 0.045 | 0.246* | 0.583 | 0.229* | 0.085 | 0.236* | −0.329 | |
| Immunosuppressive treatment | 0.205* | −0.216 | 0.136 | 0.154 | - | - | - | - | |
| >1 drug | 0.359* | 0.421* | 0.388* | 0.465 | - | - | - | - | |
| Elevated cholesterol level | 0.219* | 0.391* | 0.201 | 0.473* | 0.038 | - | −0.137 | - | |
| Elevated triglyceride level | 0.166 | 0.030 | 0.133 | −0.067 | 0.115 | - | −0.061 | - | |
| HbA1c | - | - | - | - | 0.300* | 0.145 | 0.207 | 0.128 | |
| <7% | - | - | - | - | −0.328* | −0.282 | −0.252* | −0.218 | |
| >8% | - | - | - | - | 0.255* | −0.045 | 0.189 | −0.016 | |
| Blood glucose level (elevated) | - | - | - | - | 0.187* | −0.098 | 0.026 | −0.065 | |
| BMI | 0.329* | 0.289 | 0.302* | −0.062 | 0.141 | 0.057 | −0.105 | 0.168 | |
| BMI in SDS | 0.240* | −0.082 | 0.268* | 0.191 | 0.030 | −0.042 | −0.067 | −0.281 | |
| Disease duration | 0.226* | 0.136 | 0.256* | 0.197 | 0.200* | −0.063 | −0.041 | −0.033 | |
| Age | 0.195* | 0.033 | 0.151 | 0.003 | 0.201* | 0.100 | −0.052 | 0.000 | |
| Sex | −0.006 | 0.110 | 0.149 | 0.340 | −0.038 | −0.056 | 0.131 | 0.006 | |
| R2 – coefficient of determination | - | 0.468 | - | 0.662 | - | 0.309 | - | 0.520 | |
*statistically significant correlation (P < 0.05).